| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 26 | 2024 | 5264 | 3.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 15 | 2024 | 1833 | 2.970 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2023 | 116 | 1.480 |
Why?
|
| Anus Neoplasms | 7 | 2023 | 414 | 1.420 |
Why?
|
| Hypoxia-Inducible Factor 1 | 3 | 2020 | 60 | 1.400 |
Why?
|
| Radiation-Protective Agents | 2 | 2019 | 129 | 1.240 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 5 | 2023 | 625 | 1.150 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2019 | 48 | 1.080 |
Why?
|
| Tumor Microenvironment | 11 | 2023 | 3054 | 0.990 |
Why?
|
| Uncoupling Protein 2 | 1 | 2024 | 24 | 0.920 |
Why?
|
| Insulin | 8 | 2013 | 1424 | 0.870 |
Why?
|
| Phosphatidylinositol 3-Kinases | 8 | 2010 | 1704 | 0.830 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2021 | 629 | 0.830 |
Why?
|
| Ion Channels | 1 | 2024 | 235 | 0.820 |
Why?
|
| Hypoxia | 4 | 2023 | 469 | 0.810 |
Why?
|
| Liver | 9 | 2024 | 3061 | 0.780 |
Why?
|
| Radiosurgery | 3 | 2023 | 1389 | 0.770 |
Why?
|
| Albumins | 2 | 2022 | 263 | 0.750 |
Why?
|
| Radiation Injuries | 4 | 2019 | 1476 | 0.690 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 7920 | 0.660 |
Why?
|
| Mercaptoethylamines | 1 | 2019 | 4 | 0.660 |
Why?
|
| Rectal Neoplasms | 6 | 2023 | 1240 | 0.640 |
Why?
|
| Isoquinolines | 1 | 2019 | 124 | 0.630 |
Why?
|
| Mitochondrial Dynamics | 1 | 2019 | 69 | 0.630 |
Why?
|
| Amifostine | 1 | 2019 | 99 | 0.630 |
Why?
|
| Neoplasms | 14 | 2024 | 15952 | 0.630 |
Why?
|
| Quality of Life | 5 | 2023 | 4810 | 0.620 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 623 | 0.620 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 701 | 0.610 |
Why?
|
| Radiotherapy, Image-Guided | 4 | 2024 | 340 | 0.590 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2024 | 2459 | 0.580 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2024 | 503 | 0.570 |
Why?
|
| Mitochondria | 4 | 2024 | 1293 | 0.570 |
Why?
|
| Deoxycytidine | 2 | 2022 | 1389 | 0.570 |
Why?
|
| Lipid Metabolism | 2 | 2013 | 474 | 0.560 |
Why?
|
| Glycine | 1 | 2019 | 322 | 0.550 |
Why?
|
| Duodenum | 2 | 2019 | 168 | 0.540 |
Why?
|
| Microbiota | 4 | 2023 | 545 | 0.520 |
Why?
|
| Glucose | 3 | 2013 | 1213 | 0.510 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 31 | 0.500 |
Why?
|
| Paclitaxel | 2 | 2022 | 2114 | 0.500 |
Why?
|
| Mice | 29 | 2023 | 35421 | 0.480 |
Why?
|
| Animals | 34 | 2024 | 61363 | 0.470 |
Why?
|
| Mice, Knockout | 11 | 2023 | 5692 | 0.470 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2013 | 212 | 0.450 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 2178 | 0.450 |
Why?
|
| Humans | 72 | 2024 | 270809 | 0.430 |
Why?
|
| Papillomavirus Infections | 4 | 2023 | 999 | 0.430 |
Why?
|
| Disease Models, Animal | 5 | 2022 | 7323 | 0.420 |
Why?
|
| Biomedical Research | 1 | 2020 | 800 | 0.420 |
Why?
|
| Respiratory-Gated Imaging Techniques | 1 | 2012 | 51 | 0.410 |
Why?
|
| Pandemics | 3 | 2020 | 1608 | 0.410 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 503 | 0.400 |
Why?
|
| Organs at Risk | 3 | 2020 | 559 | 0.400 |
Why?
|
| Cholangiocarcinoma | 3 | 2023 | 506 | 0.400 |
Why?
|
| Fecal Incontinence | 2 | 2023 | 90 | 0.390 |
Why?
|
| Radiotherapy | 1 | 2019 | 1858 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 13 | 2022 | 7054 | 0.390 |
Why?
|
| Clinical Trials as Topic | 5 | 2022 | 3841 | 0.370 |
Why?
|
| Receptor, Insulin | 3 | 2006 | 102 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 16752 | 0.370 |
Why?
|
| Respiration | 1 | 2012 | 465 | 0.350 |
Why?
|
| Protein Subunits | 2 | 2010 | 278 | 0.340 |
Why?
|
| Stomach | 1 | 2012 | 396 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 5606 | 0.330 |
Why?
|
| Fiducial Markers | 2 | 2020 | 95 | 0.320 |
Why?
|
| Fluorouracil | 3 | 2022 | 1990 | 0.310 |
Why?
|
| Protein Kinase C | 2 | 2009 | 414 | 0.300 |
Why?
|
| Radiotherapy Dosage | 6 | 2024 | 4020 | 0.290 |
Why?
|
| Insulin Resistance | 3 | 2009 | 720 | 0.290 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2010 | 657 | 0.290 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 5332 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2010 | 2050 | 0.290 |
Why?
|
| Signal Transduction | 7 | 2013 | 12036 | 0.280 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 4843 | 0.280 |
Why?
|
| Isoenzymes | 2 | 2007 | 644 | 0.280 |
Why?
|
| Intestine, Small | 3 | 2019 | 524 | 0.280 |
Why?
|
| Stem Cells | 4 | 2023 | 1213 | 0.270 |
Why?
|
| Radiobiology | 3 | 2021 | 56 | 0.260 |
Why?
|
| Motor Activity | 4 | 2023 | 710 | 0.260 |
Why?
|
| Oxidative Phosphorylation | 2 | 2019 | 271 | 0.260 |
Why?
|
| Radiation Oncology | 2 | 2021 | 558 | 0.260 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 305 | 0.260 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2010 | 1011 | 0.250 |
Why?
|
| Radiation Dosage | 2 | 2020 | 1042 | 0.240 |
Why?
|
| Abdomen | 3 | 2021 | 346 | 0.230 |
Why?
|
| Chemoradiotherapy | 6 | 2022 | 2038 | 0.220 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 82 | 0.220 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2023 | 879 | 0.210 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2023 | 187 | 0.210 |
Why?
|
| Male | 27 | 2024 | 128522 | 0.210 |
Why?
|
| Mitomycin | 2 | 2022 | 216 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 5247 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2193 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 334 | 0.210 |
Why?
|
| Insulin Receptor Substrate Proteins | 4 | 2013 | 131 | 0.200 |
Why?
|
| CD47 Antigen | 1 | 2022 | 28 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 1404 | 0.200 |
Why?
|
| Muscle Fatigue | 1 | 2021 | 12 | 0.200 |
Why?
|
| ADAM10 Protein | 1 | 2021 | 12 | 0.190 |
Why?
|
| Cytidine Deaminase | 1 | 2021 | 84 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2023 | 1905 | 0.190 |
Why?
|
| Ephrin-B2 | 1 | 2021 | 17 | 0.190 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2021 | 38 | 0.190 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2021 | 208 | 0.190 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 377 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2454 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 148 | 0.190 |
Why?
|
| Adipose Tissue, Brown | 3 | 2008 | 110 | 0.190 |
Why?
|
| Leucovorin | 1 | 2022 | 345 | 0.190 |
Why?
|
| Medical Writing | 1 | 2020 | 5 | 0.180 |
Why?
|
| Betacoronavirus | 3 | 2020 | 514 | 0.180 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2022 | 136 | 0.180 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2021 | 101 | 0.180 |
Why?
|
| Radiation Protection | 2 | 2019 | 204 | 0.180 |
Why?
|
| RNA Interference | 1 | 2005 | 1381 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 31 | 0.180 |
Why?
|
| Chloroquine | 1 | 2020 | 63 | 0.180 |
Why?
|
| Phosphoproteins | 2 | 2005 | 1127 | 0.180 |
Why?
|
| Health Physics | 1 | 2020 | 62 | 0.180 |
Why?
|
| Papillomaviridae | 2 | 2021 | 636 | 0.180 |
Why?
|
| Interleukin-10 | 1 | 2023 | 479 | 0.170 |
Why?
|
| Eligibility Determination | 1 | 2020 | 85 | 0.170 |
Why?
|
| Medical Oncology | 3 | 2024 | 1464 | 0.170 |
Why?
|
| Cell Transformation, Viral | 1 | 2020 | 173 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 326 | 0.170 |
Why?
|
| Female | 24 | 2024 | 148940 | 0.170 |
Why?
|
| Research Support as Topic | 1 | 2020 | 122 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 172 | 0.170 |
Why?
|
| Breath Holding | 1 | 2019 | 44 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2023 | 2659 | 0.170 |
Why?
|
| Quinazolinones | 1 | 2019 | 52 | 0.160 |
Why?
|
| Erectile Dysfunction | 1 | 2022 | 240 | 0.160 |
Why?
|
| Dynamins | 1 | 2019 | 76 | 0.160 |
Why?
|
| Laboratories | 1 | 2020 | 132 | 0.160 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 639 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1061 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 6259 | 0.160 |
Why?
|
| Oxygen | 1 | 2023 | 786 | 0.160 |
Why?
|
| Adipocytes | 3 | 2005 | 295 | 0.160 |
Why?
|
| Cisplatin | 2 | 2023 | 2509 | 0.160 |
Why?
|
| Colony-Forming Units Assay | 1 | 2018 | 253 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2022 | 2360 | 0.150 |
Why?
|
| Phosphatidylinositol Phosphates | 2 | 2010 | 44 | 0.150 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2575 | 0.150 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2009 | 40 | 0.150 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 220 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2023 | 396 | 0.150 |
Why?
|
| Fasting | 1 | 2019 | 334 | 0.150 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 3707 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 368 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 501 | 0.150 |
Why?
|
| Radiometry | 2 | 2021 | 1021 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 1580 | 0.140 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 283 | 0.140 |
Why?
|
| Phenotype | 3 | 2023 | 6503 | 0.140 |
Why?
|
| Cytokines | 2 | 2023 | 2804 | 0.140 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 127 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 339 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2021 | 1032 | 0.140 |
Why?
|
| Aged | 15 | 2024 | 73641 | 0.140 |
Why?
|
| Fibroblasts | 1 | 2023 | 1647 | 0.140 |
Why?
|
| Re-Irradiation | 1 | 2018 | 166 | 0.140 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 353 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 243 | 0.130 |
Why?
|
| Apoptosis | 4 | 2021 | 7757 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2018 | 368 | 0.130 |
Why?
|
| Patient Selection | 2 | 2022 | 2032 | 0.130 |
Why?
|
| Research Design | 2 | 2020 | 1562 | 0.130 |
Why?
|
| Inflammation | 2 | 2023 | 2491 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2021 | 4148 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 362 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 255 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1691 | 0.120 |
Why?
|
| Endosonography | 1 | 2018 | 551 | 0.120 |
Why?
|
| Circulating Tumor DNA | 1 | 2018 | 277 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2022 | 747 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 445 | 0.120 |
Why?
|
| Gluconeogenesis | 2 | 2006 | 127 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2019 | 1592 | 0.120 |
Why?
|
| Cell Communication | 1 | 2017 | 509 | 0.120 |
Why?
|
| Amino Acids, Dicarboxylic | 1 | 2014 | 1 | 0.120 |
Why?
|
| Prolyl-Hydroxylase Inhibitors | 1 | 2014 | 6 | 0.120 |
Why?
|
| Models, Biological | 2 | 2017 | 3187 | 0.120 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2012 | 61 | 0.120 |
Why?
|
| Hematocrit | 1 | 2014 | 149 | 0.110 |
Why?
|
| Pancreatitis | 1 | 2016 | 296 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2019 | 5416 | 0.110 |
Why?
|
| Middle Aged | 14 | 2024 | 90570 | 0.110 |
Why?
|
| Physicians | 1 | 2022 | 854 | 0.110 |
Why?
|
| Chelating Agents | 1 | 2014 | 131 | 0.110 |
Why?
|
| Protein Isoforms | 2 | 2014 | 843 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2016 | 606 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 4495 | 0.110 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14886 | 0.110 |
Why?
|
| Exhalation | 1 | 2012 | 61 | 0.100 |
Why?
|
| Proteins | 2 | 2021 | 2030 | 0.100 |
Why?
|
| Transcriptome | 1 | 2021 | 1960 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2007 | 1801 | 0.100 |
Why?
|
| Registries | 1 | 2020 | 2212 | 0.100 |
Why?
|
| United States | 4 | 2024 | 15834 | 0.100 |
Why?
|
| Disease Progression | 4 | 2019 | 6881 | 0.100 |
Why?
|
| Appetite | 1 | 2012 | 65 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 1944 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2021 | 2922 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 322 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2023 | 5681 | 0.090 |
Why?
|
| Heterozygote | 1 | 2014 | 1057 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 1469 | 0.090 |
Why?
|
| Hepatitis, Chronic | 1 | 2010 | 14 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2022 | 2413 | 0.090 |
Why?
|
| Anal Canal | 2 | 2022 | 237 | 0.090 |
Why?
|
| Adult | 10 | 2024 | 82074 | 0.090 |
Why?
|
| Calibration | 2 | 2022 | 346 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 1282 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10409 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2023 | 13422 | 0.080 |
Why?
|
| Movement | 1 | 2012 | 565 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 7789 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 4103 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2009 | 1045 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 12535 | 0.080 |
Why?
|
| Margins of Excision | 2 | 2022 | 315 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2015 | 1034 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4470 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10731 | 0.080 |
Why?
|
| Proton Therapy | 1 | 2019 | 1637 | 0.080 |
Why?
|
| Adipogenesis | 1 | 2008 | 98 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 14037 | 0.070 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 220 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 245 | 0.070 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2007 | 46 | 0.070 |
Why?
|
| Obesity | 2 | 2012 | 2893 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3656 | 0.070 |
Why?
|
| Survivors | 2 | 2022 | 1022 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 1127 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4971 | 0.070 |
Why?
|
| Fatigue | 2 | 2023 | 1292 | 0.060 |
Why?
|
| Prevalence | 2 | 2023 | 3395 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2024 | 39982 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 1 | 2007 | 330 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 1536 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2007 | 335 | 0.060 |
Why?
|
| Phantoms, Imaging | 2 | 2020 | 1330 | 0.060 |
Why?
|
| Receptors, Leptin | 1 | 2023 | 65 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2023 | 57 | 0.060 |
Why?
|
| Pancreatectomy | 2 | 2018 | 696 | 0.060 |
Why?
|
| Leptin | 1 | 2005 | 302 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2020 | 2033 | 0.050 |
Why?
|
| Defecation | 1 | 2023 | 58 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 1105 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 2394 | 0.050 |
Why?
|
| Mutation | 2 | 2023 | 15922 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2008 | 985 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2356 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 688 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 210 | 0.050 |
Why?
|
| Biopsy | 2 | 2021 | 3490 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2009 | 1555 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 1162 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 64 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2005 | 437 | 0.050 |
Why?
|
| Azides | 1 | 2001 | 34 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 312 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2006 | 704 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 601 | 0.050 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 78 | 0.050 |
Why?
|
| Credentialing | 1 | 2021 | 61 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 391 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2021 | 33860 | 0.050 |
Why?
|
| Zambia | 1 | 2020 | 16 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 9048 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 228 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2018 | 5658 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2018 | 2313 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 76 | 0.040 |
Why?
|
| Postal Service | 1 | 2020 | 17 | 0.040 |
Why?
|
| Antimalarials | 1 | 2020 | 55 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 255 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 31117 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2022 | 333 | 0.040 |
Why?
|
| Research | 1 | 2022 | 421 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 437 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 79 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 509 | 0.040 |
Why?
|
| Homeostasis | 1 | 2005 | 925 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2018 | 3463 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2003 | 486 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 179 | 0.040 |
Why?
|
| X-Rays | 1 | 2020 | 151 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2020 | 92 | 0.040 |
Why?
|
| Peer Review | 1 | 2020 | 82 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 243 | 0.040 |
Why?
|
| Benchmarking | 1 | 2021 | 276 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2005 | 1490 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 58 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2019 | 230 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 207 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 352 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 1276 | 0.040 |
Why?
|
| Pelvis | 1 | 2021 | 383 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 2192 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 680 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1409 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 425 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 4198 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 482 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 481 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 167 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2022 | 1715 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 728 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 12045 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 739 | 0.040 |
Why?
|
| Rectum | 1 | 2020 | 480 | 0.040 |
Why?
|
| Uncertainty | 1 | 2019 | 327 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1581 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 231 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 307 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 12979 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 751 | 0.040 |
Why?
|
| Ceruletide | 1 | 2016 | 28 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2005 | 4105 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2018 | 626 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2021 | 593 | 0.030 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2016 | 44 | 0.030 |
Why?
|
| Artifacts | 1 | 2020 | 537 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 327 | 0.030 |
Why?
|
| Risk | 1 | 2021 | 1931 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 585 | 0.030 |
Why?
|
| Nitriles | 1 | 2001 | 939 | 0.030 |
Why?
|
| Regeneration | 1 | 2019 | 284 | 0.030 |
Why?
|
| Biological Products | 1 | 2020 | 318 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2006 | 6344 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 1336 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1329 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 425 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 2618 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1096 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 2300 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 1581 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 315 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 60 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1098 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 1391 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 757 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 2272 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 914 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 800 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 3435 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 15280 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1828 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 758 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1246 | 0.030 |
Why?
|
| Incidence | 1 | 2023 | 5824 | 0.030 |
Why?
|
| Age Factors | 2 | 2020 | 5443 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 1837 | 0.030 |
Why?
|
| Prognosis | 2 | 2022 | 22533 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 3058 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 124 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 3582 | 0.020 |
Why?
|
| Histones | 1 | 2019 | 1512 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 4007 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 2170 | 0.020 |
Why?
|
| Acute Disease | 1 | 2016 | 2492 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1992 | 212 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 4320 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5050 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 1992 | 193 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 4969 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1437 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 5146 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 1043 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4966 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 10268 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2018 | 9281 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 3946 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 201 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 1152 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2008 | 69 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3429 | 0.020 |
Why?
|
| Thermogenesis | 1 | 2008 | 49 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6193 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2008 | 93 | 0.020 |
Why?
|
| Muscles | 1 | 2009 | 443 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2009 | 598 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 3190 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7647 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 1902 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 3908 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 344 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 9054 | 0.020 |
Why?
|
| Triglycerides | 1 | 2009 | 610 | 0.020 |
Why?
|
| Cholesterol | 1 | 2009 | 656 | 0.020 |
Why?
|
| E2F4 Transcription Factor | 1 | 2005 | 30 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 196 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1992 | 1155 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2009 | 1254 | 0.010 |
Why?
|
| PPAR gamma | 1 | 2005 | 224 | 0.010 |
Why?
|
| Azo Compounds | 1 | 2003 | 15 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2003 | 26 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 54 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 347 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 3567 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2005 | 384 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1416 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 541 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 232 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 22255 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 372 | 0.010 |
Why?
|
| Alkenes | 1 | 2001 | 12 | 0.010 |
Why?
|
| Aldehydes | 1 | 2001 | 45 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 887 | 0.010 |
Why?
|
| Palladium | 1 | 2001 | 56 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 17867 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 245 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 923 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2008 | 4332 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 771 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 32698 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 5313 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 6397 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 610 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 1388 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 2478 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1494 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 884 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 2087 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 4905 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 4993 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 449 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1992 | 537 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1992 | 942 | 0.000 |
Why?
|